Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

156P - High TLR3 expression predicts improved survival in patients with clear cell renal cell carcinoma

Date

17 Sep 2020

Session

E-Poster Display

Topics

Translational Research

Tumour Site

Presenters

Mingjia Li

Citation

Annals of Oncology (2020) 31 (suppl_4): S274-S302. 10.1016/annonc/annonc266

Authors

M. Li1, Z. Li2, P. Kalinski3, C. Verschraegen2, S. Clinton2, Y. Yang2, A. Mortazavi2, P. Monk2, E. Folefac2, M. Yin2, A. Parikh2, Y. Yang2

Author affiliations

  • 1 Internal Medicine, The Ohio State University Wexner Medical Center, 43210 - Columbus/US
  • 2 Medical Oncology, Ohio State University, 43210 - Columbus/US
  • 3 Medical Oncology, Roswell Park Comprehensive Cancer Center, 14203 - Buffalo/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 156P

Background

Toll-like receptor 3 (TLR3) is an innate immune pattern recognition receptor that can be activated by viral dsRNA and damage-associated molecular patterns, such as self-derived RNA from tissue necrosis. TLR3 signaling has a unique role in in promoting tumor-infiltrating cytotoxic T lymphocyte (CTL), it is associated with improved clinical outcome in patients (pts) with clear cell renal cell carcinoma (ccRCC). In this study, we assess the prognostic value of TLR3.

Methods

Genomic and clinically data were obtained from The Cancer Genome Atlas PanCancer Atlas databases. Pts with RNA-seq data at all stages were included. The mean TLR-3 mRNA expressions in transcript per million were compared by Wilcoxon tests. ccRCC pts were divided into TLR-3 high and low groups, at the 50th percentile. The progression free survival (PFS) and overall survival (OS) differences were compared between the two groups and the significance was determined by Log-rank test. The OS was modeled as a function of TLR3 expression, cancer stage, and tumor grade using Cox regression in a multivariate analysis.

Results

510 ccRCC pts were included and 83 (16.3%) had stage IV diseases. ccRCC had highest TLR3 mRNA expression among the 19 solid tumor types studied in TCGA (p<0.001). The mean TLR3 expression of primary ccRCC was 5.5-fold higher than the next highest expresser (papillary RCC, n=290) and 9.9-fold higher than the mean of the 17 others. Among the 72 pts with matched benign kidney tissue, 67 (93%) had increased TLR3 expression in the cancer. On average, there was 225% increase of intratumoral TLR3 expression compared to the benign counterpart tissue (p<0.001). The median OS was not reached (NR) in TLR3 high (95% CI: 93m-NR) vs. 62m in TLR3 low (95% CI: 52.2-79.5m). The hazard ratio (HR) was 0.41 (p<0.001). High TLR3 was associated with improved PFS (HR=0.44, 95% CI: 0.31-0.61). In multivariate analysis, high TLR3 predicts better OS independent of stage and grade (HR=0.40, CI 95% 0.23-0.57, p<0.001).

Conclusions

High intratumoral TLR3 expression at the time of nephrectomy may be an independent predictor of improved survival in pts with ccRCC. Future studies are needed to further delineate the relationships between TLR3 expression, CTL recruitment, and anticancer immune response.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.